Prostate Cancer International is
for 2011 by Great NonProfits
Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, continuous, hormone therapy, intermittent, outcome, survival | 1 Comment »
The key prostate cancer presentations today at the annual meeting of the American Society of Clinical Oncology (ASCO) were all given at a morning session on high-risk and advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, MDV3100 | 2 Comments »
Data to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) on Sunday, June 3, suggest that African American men with localized prostate cancer may be less likely that Caucasian men to respond well to active surveillance as a management strategy. However, this conclusion comes from a retrospective analysis of [...]
Filed under: Diagnosis, Management, Living with Prostate Cancer, Risk | Tagged: active surveillance, African American, ethnicity, progression, race, risk | 1 Comment »
Studies to be presented at the ASCO meeting next week suggest that: (a) high-dose ketoconazole has very limited activity in the treatment of men who have already been treated with abiraterone acetate; (b) men treated with either high-dose ketoconazole or abiraterone acetate (or both) can still respond to docetaxel-based chemotherapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, chemotherapy, CRPC, ketoconazole, outcome, sequence | 1 Comment »
A paper to be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) suggests that, at least in Sweden, the combination of an increase in PSA testing, early diagnosis, and treatment with curative intent has decreased the risk for and incidence of lethal prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, incidence, lethal, mortality, PSA, risk, test | 12 Comments »
A poster to be presented at the upcoming ASCO annual meeting gives us some insights into the actual behaviors of physicians and their patients regarding the use of active surveillance today in the “real world” of clinical practice (as opposed to clinical trials and case series at academic medical centers).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active surveillance, low risk, Management | 4 Comments »
A paper presented earlier this week at the annual meeting of the American Urological Association in Atlanta suggests that a drug called cabergoline may have the ability to induce the return of orgasm in men with anorgasmia (the persistent or frequent absence of orgasm after normal sexual arousal). The available data suggests that the patients [...]
Filed under: Living with Prostate Cancer, Management | Tagged: anorgasmia, cabergoline, orgasm, radical prostatectomy | 4 Comments »
Many readers of this blog will enjoy reviewing the editorial commentary in today’s issue of the influential USA Today, entitled “Skipping prostate test can kill“.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, PSA, risk, USPSTF | 7 Comments »
How did we all miss this? This may be the single most important paper presented at the annual meeting of the American Urological Association this year!
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: air, misinformation, risk, spread | 5 Comments »
Dan Zenka, a prostate cancer patient and a Senior VP with the Prostate Cancer Foundation, appears to have published one of the more intelligent responses to the USPSTF recommendation on PSA screening since Monday’s announcement. Have a look at his blog post.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: PSA, risk, screening, test, USPSTF | 9 Comments »
An article in The Washington Post today discusses an initiative through which a group of about 40 specialists in the management of advanced forms of genitourinary cancers (including prostate cancer) get together to share ideas and knowledge to help their patients.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, GUMDROP, referral, trials | Leave a Comment »
Acccording to an article on the Medscape web site today, the convicted “Lockerbie bomber,” Abdelbaset al Megrahi, finally died on Sunday, 2 years and 9 months after his release from a Scottish prison on compassionate grounds because he was close to dying of terminal prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, al Megrahi, survival | 9 Comments »
A Letter to the Editor just published in the journal Nature Genetics has suggested that that so-called SPOP mutations may be responsible for between 6 and 15 percent of the prostate cancers diagnosed in the USA each year.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gene, mutation, SPOP, subtype, targeted | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site